#892 MDC team has explained the pivotal role of the transcription factor C/EBPb in the secretion process in the lungs’ alveoli

… proved barely able to proliferate. An important piece of…

#893 Keeping aggressive cancer cells in check

… Delbrück Center has now reported in The EMBO Journal how…

#894 Scientists from Charité profiled 168 metabolic markers in blood samples and were able to predict the risk of onset of several diseases with just one test

… the form of medication or lifestyle changes,” says…

#895 NUVISAN receives US$ 9.6m grant for a multi-target drug discovery program on novel non-hormonal contraceptive medicines

NUVISAN’s integrated drug discovery expertise leveraged in a grant from the Bill & Melinda Gates Foundation Berlin, Germany, 20 September 2022: NUVISAN ICB GmbH, a fully integrated contract research

#896 PRAMOMOLECULAR wants to silence cancer

PRAMOMOLECULAR GmbH, a spin-off of the Technische Universität Berlin, uses gene silencing to down-regulate cancer proteins and thus reduce tumor growth. This makes it possible to address cancers in a

#897 Algorithms developed at the Max Delbrück Center are able to detect new SARS-CoV-2 variants and other pathogens in wastewater

But that’s not all: the tool, which Altuna Akalin and his colleagues have now presented in “Science of the Total Environment”, can also find other pathogens. SARS-CoV-2 is one of many pathogens

#898 Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility

Berlin, Germany and BELOIT, Wis., 11 October 2022 - Eckert & Ziegler Isotope Technologies Dresden (ITD), a specialist for radiopharmaceutical plant engineering and fully owned subsidiary of Eckert

#899 T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial

… cancers, no reported protein expression in…

#900 FyoniBio and Strike Pharma sign a Master Service Agreement covering Cell Line Development for a novel bi-specific therapeutic mAb

Berlin, Germany and Stockholm, Sweden, October 20, 2022: FyoniBio, a CDO expert specialized in tailored cell line development and Strike Pharma, whose proprietary Adaptable Drug Affinity Conjugate

#901 BIH Digital Health Accelerator Program 2024

Application Deadline: Friday, 3 November, 2023 at 6pm (CET) How to accelerate your idea? Apply for the BIH Digital Health Accelerator Program 2024 to receive support in building your innovative

#902 First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial

Berlin/Aalborg, 27 October 2022. The University Hospital Aalborg (Denmark) yesterday has imaged the first patient with Eckert and Ziegler’s Gallium (68Ga) boclatixafortide (PENTIXAFOR) in an

#903 CELLphenomics, KYAN Technologies and Alentis Therapeutics join forces

Berlin, Singapore, Allschwil 9-29-2023 CELLphenomics and KYAN Technologies, a vanguard combinatory drug development solutions provider, are thrilled to announce a strategic partnership with Alentis

#904 Data4Life supports developing an early warning system for crises with the digital study DAKI Health

… DAKI-FWS project, Data4Life contributes to the early…

#905 Charité research team discovers central functions of innate immune cells

… over the course of a lifetime, and the innate immune…

#906 LABORATORY EQUIPMENT MANUFACTURER KNAUER HONORED AS TOP EMPLOYER

As the Berlin-based company KNAUER announced on October 12, it is one of the most attractive employers in Germany according to a recent meta-study (top 1% of more than 74,000 employers

#907 Three proteins in the blood help to early detect type 2 diabetes risk

… would enable preventive lifestyle and behavioural…

#908 Eckert & Ziegler establishes German-Chinese joint venture with DC Pharma for the production of radioisotopes

Eckert & Ziegler (ISIN DE0005659700) strengthens its competitive position in the growth market of China and today signed a 50:50 joint venture agreement with the Chinese pharmaceutical company

#909 TME PHARMA ANNOUNCES THE INITIATION OF THE LISTING OF PREFERENTIAL SUBSCRIPTION RIGHTS FOR FULLY GUARANTEED €2.7 MILLION CAPITAL INCREASE

- Guaranteed portion of the transaction will extend cash runway past regulatory milestones in Q1-2024 - The financial visibility will allow TME Pharma to file and receive feedback from FDA on its

#910 How genes and small molecules influence our personal disease risk

… which is consistent with reports from drug studies," she…

#911 Study published in Science by Charité Universitätsmedizin sheds light on the origins of the SARS-CoV-2 variant

…harite.de/en/service/press_reports/artikel/detail/where_did_om…

#912 Drug for liver disease could protect against infection with SARS-CoV-2 and help COVID-19 patients

… of the ACE-2 receptor", reports Vallier. The mechanism…

#913 BIOTRONIK Opens New Asia-Pacific Hub in Singapore

New Asia-Pacific Hub Strengthens Singaporean MedTech Ecosystem BIOTRONIK announced today the opening of its new Asia Pacific Manufacturing and Research Hub. The 20,000 m² site will serve as

#914 Competition call for the Deep Tech Award

Deadline: April 26, 2024 Deep Tech Berlin is the campaign of the Senate Department for Economics, Energy, and Enterprises and has been conducted since 2015. Its aim is to support Berlin-based

#915 Charité study shows that algorithm is equivalent to standard of care treatment

…harite.de/en/service/press_reports/artikel/detail/deep_brain_s…

#916 Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) has discovered an unknown mechanism for how “starvation response” in body cells is triggered

… response to starvation,” reported Volker Haucke. When cells…

#917 Professor Il-Kang Na named new director of the BIH Charité Clinician Scientist Program

Prof. Il-Kang Na became the new director of the BIH Charité Clinician Scientist Program (CSP) on January 1, 2023. The BIH Johanna Quandt Professor succeeds Prof. Duška Dragun, who headed the CSP

#918 ProBioGen Collaborates with Boehringer Ingelheim on DirectedLuck® Transposase Technology

ProBioGen announced today a new non-exclusive collaboration with Boehringer Ingelheim on ProBioGen's DirectedLuck® transposase technology. ProBioGen and Boehringer Ingelheim have a long legacy of

#919 Prof. Dr. Joachim Spranger is the new Dean of Charité

…harite.de/en/service/press_reports/artikel/detail/prof_dr_joac…

#920 Pioneering method for stem cell diagnostics: Leif S. Ludwig receives Paul Ehrlich and Ludwig Darmstaedter Early Career Award

… that can analyse the lifelong regeneration of cells in…

#921 Scientists of Max Planck Institute for Molecular Genetics have reconstructed chromosomes of patients with a high number of aberrations in their genome that potentially cause disease

… 2011, scientists reported that sometimes DNA can…

#922 ProBioGen Collaborates with Boehringer Ingelheim on DirectedLuck® Transposase Technology

ProBioGen announced today a new non-exclusive collaboration with Boehringer Ingelheim on ProBioGen's DirectedLuck® transposase technology. ProBioGen and Boehringer Ingelheim have a long

#923 Eckert & Ziegler Extends Ga-68 Activities in Japan

Berlin, Germany – 28 February 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) expands its activities on Gallium-68 (Ga-68) labeled diagnostics in Japan together with Novartis Pharma K.K.

#924 JOIN OUR NEXT COHORT

Application deadline: April 3 Vision Health Pioneers Incubator offers a 9-month startup program that supports first-time founders from Europe in launching their healthcare startups. Teams that enter

#925 Researchers of Max Delbrück Center develop a new method that is able to identify “zipcodes” that assign a destination to mRNAs

Decoding cellular zipcodes Researchers suspect that neurodegenerative diseases occur when messenger RNA (mRNA) goes astray in the neuron. With a new method, Marina Chekulaeva is able to identify

#926 8th BioProScale Symposium 2024

SCALING DOWN AND UP OF BIOPROCESSES: STRATEGIES, TOOLS AND PROCESS PERFORMANCE The BioProScale Symposium is an event on industrial scale bioprocessing with a long scientific tradition. Target

#927 Study in Nature discovers causal mechanism behind rare hereditary diseases

…harite.de/en/service/press_reports/artikel/detail/study_in_nat…

#928 1.3 million euros for ten new projects in 3R research

…harite.de/en/service/press_reports/artikel/detail/13_million_e…

#929 Identification of disease-causing proteins leads to new potential treatments for diseases like diabetes

… about their diet, lifestyle and health through…

#930 Max Delbrück Center reveals the harmful effects of immune cells in hypertension

… the Max Delbrück Center reports in Cardiovascular…

#931 ProBioGen’s Growth Strategy Continues Successfully

… on to holistic Customer Lifecycle Marketing. "I join…

#932 Transparency for clinical trials

… centers in Germany,” reports Delwen Franzen, a research…

#933 Using bone marrow stromal cells instead of transplantation

Bone is the second most commonly transplanted tissue after blood, with about two million bone transplants performed worldwide each year – but often with only moderate therapeutic success. Cell-based

#934 Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

Berlin, Germany and Indianapolis, Indiana, USA – 4 April 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed

#935 Patient Monitoring Roundtable No°1 | 2024 – Monitoring in zero gravity: findings from space research (in German)

The Patient Monitoring Roundtable is an interdisciplinary platform for an inspiring exchange between clinicians, industry and patient representatives. A key feature is the joint commitment to

#936 ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients

Berlin, Germany and Zurich, Switzerland – April 12, 2023 ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical

#937 Cellphenomics’ And Kyan Therapeutics Combined Platforms Provide Best-In-Class Solutions To Support The Biopharma Industry

Berlin/Singapore (April 14, 2023) CELLphenomics and KYAN Therapeutics announced their new partnership today. By combining KYAN's technology platform, Optim.AI™ - which utilizes artificial

#938 Max Delbrück Center discovers how non-coding parts of the genome drive evolution

… at the Max Delbrück Center reports in “Nature”.

#939 Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177

Berlin, 20 April 2023 - Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), has received the manufacturing authorization

#940 How cancer genes become independent

Sometimes a tumor suddenly starts growing rapidly or becomes resistant to cancerdrugs. This can be caused by a cancer gene “striking out on its own” in ring shapes. ECRC-scientist Anton Henssen

#941 GeneQuine Biotherapeutics Changes Name to GQ Bio Therapeutics, Expands Facilities and Appoints Industry Veteran to Board

Hamburg, Germany, May 9, 2023 – GeneQuine Biotherapeutics GmbH today announced that it is changing its name to GQ Bio Therapeutics GmbH. Since 2012, the company has been working under the name

#942 Clinical trial run by Charité and the Max Delbrück Center has been awarded a grant of several million euros to test a new immunotherapy approach

While CAR-T cells have proven successful in treating certain types of leukemia and lymphoma, these immunotherapies can become even more effective. A clinical trial run by Charité and the Max Delbrück

#943 Researchers from the Max Delbrück Center and the DZHK are exploring how the effects of a mutated gene that causes severe hypertension but also protects the kidneys from being damaged can be used therapeutically

… from being damaged, reports a team led by Enno…

#944 Max Delbrück Center has investigated how the sensory cells of the vagus nerve react to mechanical stimuli in the esophagus in the process of swallowing

Sensory cells in the vagus nerve can detect and locate food in the esophagus. Their signals help transport the food onward to the stomach. Signal failure leads to swallowing disorders, say a team led

#945 Charité assumes presidency of the European University Hospital Alliance (EUHA)

… by collecting patient-reported outcome measures (PROMs),…

#946 Max Delbrück Center has developed new technology to study virus infections

… SARS-CoV-2 infection. As reported in "Science Advances" by…

#947 Max Delbrück Center has developed a new tool to study complex genome interactions

… to study DNA interactions, reports a new study in “Nature…

#948 Scientists from BIH and Max Delbrück Center discover that T cells of the immune system are especially sensitive to genetic disturbances within their mitochondrial power plants

… T cells need to proliferate substantially, and we…

#949 World Health Summit 2023: "A Defining Year for Global Health Action" - Registration for WHS 2023 is open

Climate change and health, digital technologies for global health, pandemic prevention, the global health priorities of the G7/G20 nations, and the 75th anniversary of WHO are the focus of this

#950 xTEF 2024 Event | All TEFs Open for Business

Ready for a glimpse into the future of AI? The xTEF 2024 Event in Berlin on March 4 is where it all begins. Explore the pinnacle of European AI innovation with AI-Matters, Agrifood TEF, Citcom.ai,

#951 New muscle therapy gets fast-track boost - The stem cell therapy developed by MyoPax, a spin-off from the Max Delbrück Center and Charité, could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process

… development and causes lifelong incontinence. About one…

#952 CMC 2024 „DISTILLED“ ONLINE CONFERENCE - Update on Women’s Cancer

The clinical and scientific update covers the highlights in breast cancer, ovarian, cervical and endometrial cancer. An exclusive agenda with presidential lectures, state of the art sessions,

#953 Max Delbrück Center scientists contribute to study that created the most comprehensive cell atlas of the human heart which include the cells from which the heartbeat originates

… atlas of the human heart. As reported in the journal “Nature”,…

#954 GOOD CLINICAL PRACTICE (GCP) – ONLINE BASIC TRAINING

… preparation, conduct and reporting of clinical trials. GCP…

#955 Preparations for new Einstein Center begin

With a grant of 600,000 euros, the Einstein Foundation Berlin is funding the preliminary module for an Einstein Center for Early Disease Interception. Ten Berlin institutions – including the Max

#956 GOOD CLINICAL PRACTICE

… preparation, conduct and reporting of clinical trials. GCP…

#957 GQ Bio Closes Collaboration Deal with Pacira BioSciences for Development of a Commercial-Scale Manufacturing Process for High-Capacity Adenoviral Vectors

… deal with Pacira BioSciences, Inc. for the development…

#958 Rapid and Specific Detection of most common Fungal Nail and Skin Infections

… the changes in global lifestyle (synthetic shoes,…

#959 Rare kidney disease is genetically decoded

… detail. They have now reported their findings in “Genome…

#960 3Z and biotx.ai forge partnership to advance ADHD drug development using AI modelling

Reykjavik, Iceland and Berlin, Aug. 18, 2023 — Reykjavik-based drug discovery company, 3Z, and Germany/US-based causal AI firm, biotx.ai, have joined forces in a strategic partnership aimed at

#961 Pre-call Announcement

… with environmental and lifestyle factors. Thus, the…

#962 G4A: Growth Track

… Challenges Lifestyle Behavior Change,…

#963 Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update

The patient population that benefits most from treatment with enibarcimab in septic shock can be clearly defined by two biomarkers, according to data presented today In the AdrenOSS-2 study, the

#964 Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients

Collaboration will develop and market Satellite Hot Labs for radiolabeling of BioGuides Berlin, Germany – 13 September 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) today announced they

#965 Starting up with highly promising immunotherapies

After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario

#966 2024 BIH Digital Health Accelerator Demo Day

Moderator: Tjaša Zajc, Digital Health Expert, Host of internationally renowned Faces of Digital Health podcast; Advisory Board Member of the HIMSS Impulse speaker: Dr. Johanna Ludwig,

#967 Eckert & Ziegler Receives Award for Professional Training

Eckert & Ziegler AG has been awarded the Pankow 2023 Training Prize for outstanding training quality. The award was presented yesterday at a celebration event by Berlin-Pankow District Mayor Dr.

#968 From INNATE to ADAPTIVE Immunity - a question of memory

Berlin Symposium | 1-2 July 2024 The symposium From Innate to Adaptive Immunity – a question of memory is being jointly organised by the Deutsches Rheuma‐Forschungszentrum Berlin (DRFZ), a

#969 Scientists from the Max Delbrück Center have created a new zebrafish xenograft platform to screen for novel treatments for glioblastoma

Scientists have created a new zebrafish xenograft platform to screen for novel treatments for an aggressive brain tumor called glioblastoma, according to a new study by the Gerhardt and De Smet labs

#970 Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials

Eckert & Ziegler (ISIN DE0005659700, SDAX) and Ablaze Pharmaceuticals (Ablaze)signed a comprehensive supply agreement for non-carrier added Lutetium-177 (n.c.a. 177Lu). Eckert & Ziegler will serve as

#971 How stem cells and immune cells communicate - Lisec Artz Award for Simon Haas

Blood cancer is often driven by mutations in stem cells, which are key target cells in the search for innovative early-stage therapies. Dr. Simon Haas, head of a lab within the joint research focus

#972 Personalized cancer medicine: humans make better treatment decisions than AI - Charité study highlights limits of large language models in precision medicine

… AI in isolated cases,” Benary reports. “But large language…

#973 Recent Charité study of the mRNA coronavirus vaccines shows how the body builds local immune memory in various organs

…harite.de/en/service/press_reports/artikel/detail/coronavirus_…

#974 Caresyntax Announces Strategic Collaboration with AAICO to Expand AI-based Solutions In Healthcare

SAN FRANCISCO, December 5, 2023 — Caresyntax has entered into a strategic collaboration with The Applied AI Company (AAICO), a leading AI technology company, to distribute novel software and

#975 Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening

WILMINGTON, Mass. & BERLIN--(BUSINESS WIRE)--Dec. 12, 2023-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with CELLphenomics, a

#976 Scientists of the Max Delbrück Center describe the role one enzyme plays in removing waste DNA or RNA remains in cells

If waste DNA or RNA remains in cells, it can lead to diseases such as Alzheimer’s and autoimmune conditions. Writing in Nucleic Acids Research, scientists led by Oliver Daumke of the Max Delbrück

#977 Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates

Eckert & Ziegler (ISIN DE0005659700, SDAX) and ARTBIO, Inc. (ARTBIO), a clinical-stage biotechnology company specializing in the development of a new class of alpha radioligand therapies (ARTs), have

#978 Third ERC Grant for Gaetano Gargiulo from the Max Delbrück Center

… called SynT, a synthetic reporter system designed to…

#979 For faster access to gene and cell therapies in Europe - EU-funded JOIN4ATMP project aims to overcome regulatory obstacles

…harite.de/en/service/press_reports/artikel/detail/for_faster_a…

#980 Computer-engineered DNA to study cell identities

… time, the state of cells. Reported by the Gargiulo lab in…

#981 How COVID-19 affects the brain - Neurological symptoms apparently not a result of SARS-CoV-2 infection of the brain

… in the brain, let alone proliferate,” explains Dr. Helena…

#982 A new channel for touch

Touch is a fundamental, yet scarcely understood, sense. Now, the team led by Gary Lewin at the Max Delbrück Center has discovered a second ion channel associated with touch perception. Elkin1 could

#983 BIOTRONIK Introduces World’s First and Only System CE Approved for Left Bundle Branch Area Pacing (LBBAP) | Biotronik

BIOTRONIK Launches Its Complete Conduction System Pacing (CSP) Solution Consisting of the World’s First Approved CSP System Alongside Comprehensive Training and Expert Support Following the recent

#984 Bayer and Aignostics to collaborate on next generation precision oncology

Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development, further strengthening Bayer’s precision oncology development

#985 Charité Virology is a reference laboratory in the WHO Coronavirus Network CoViNet - Global network of reference laboratories aims to detect and monitor coronaviruses

The World Health Organization (WHO) has selected the Institute of Virology at Charité – Universitätsmedizin Berlin as a member of the newly established WHO Coronavirus Network (CoViNet). The global

#986 New Data at LINC 2022 Confirm Passeo-18 Lux Drug-Coated Balloon is a Safe and Effective Treatment in Challenging Patient Groups

… University Graz, Austria, reported the results of the…

#987 Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer

… clinical data previously reported from INSIGHT-004 in…

#988 MIT Covid19 Challenge

… testing (capacity, cost, reporting and speed), and any…

#989 GOOD CLINICAL PRACTICE (GCP)

… preparation, conduct and reporting of clinical trials. GCP…

#990 Announcement - 1st German-Swedish Call for Proposals for joint R&D projects by Small and Mediumsized Enterprises (SMEs)

… of benefits Joint final reporting is to be done according…
Show more items